Welcome to our dedicated page for NewcelX SEC filings (Ticker: NCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NewcelX Ltd. (Nasdaq: NCEL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. NewcelX reports under the Exchange Act on Form 20-F and furnishes current reports on Form 6-K, offering investors structured insight into its operations as a Swiss clinical-stage biopharmaceutical and biotechnology company focused on neurodegenerative and metabolic diseases.
Through these filings, readers can follow key corporate events connected to the merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd., which established NewcelX as a combined entity integrating cell-therapy platforms with neuroscience and small-molecule expertise. For example, a Form 6-K details the post-merger appointment of Kost Forrer Gabbay & Kasierer, a member of Ernst & Young, as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and describes the prior engagement and dismissal of CBIZ CPAs, P.C., along with references to previously disclosed material weaknesses.
On Stock Titan, NewcelX filings such as annual reports on Form 20-F, interim and event-driven Form 6-K submissions, and related exhibits can be viewed alongside AI-powered summaries. These summaries are designed to highlight essential elements of lengthy documents, helping users quickly identify information on topics like accounting firm changes, internal control disclosures, merger-related details, and other governance matters discussed in the filings.
Investors researching NCEL can use this page to monitor how NewcelX describes its business, risk factors, financial reporting framework, and post-merger integration steps over time. Real-time updates from EDGAR combined with AI-assisted overviews aim to make complex regulatory content more accessible without replacing the need to review the full original filings.
NewcelX Ltd. announced a private placement financing with accredited investors, selling 490,907 common shares (or pre-funded warrants) at $2.75 per share, a 30% premium to the prior closing price, and issuing common warrants to purchase up to 687,270 shares at an exercise price of $3.025 per share.
The transaction is expected to provide gross proceeds of $1.35 million, with an additional approximately $2.1 million possible from full cash exercise of the warrants. NewcelX plans to use the proceeds, alongside its previously announced $25 million equity line, to advance NCEL-101, its lead stem-cell-based therapy program for Type 1 Diabetes, as well as other pipeline programs, working capital and general corporate purposes.
The offering is expected to close on or about April 15, 2026, subject to customary closing conditions, and the securities are being issued under Section 4(a)(2) and Rule 506(b) of Regulation D, with a commitment to file a resale registration statement for the underlying shares.
NewcelX Ltd. director Galili Tamar filed an initial ownership report showing an option to purchase 9,117 ordinary shares. The option has an exercise price of $7.6200 per share and expires on November 4, 2035. As of this filing, options to purchase 759 ordinary shares are vested and currently exercisable, while the remaining options vest in 11 equal quarterly installments beginning on May 4, 2026, subject to continued service. The options were granted under the NewcelX Ltd. Share Option Plan Regulation 2021 and, to qualify for certain Israeli tax benefits, must be registered in the name of a trustee.
NewcelX Ltd. director, Chairman and CEO Ronen Twito has filed an initial Form 3 showing beneficial ownership of 272,399 Ordinary Shares of the company. According to the disclosure, these shares are held by Altshare Trust Ltd on his behalf under Section 102 of the Israeli Tax Ordinance. The filing records his starting equity position as an insider, without reporting any specific recent share purchases or sales.
NewcelX Ltd. CSO and director Revel Michel filed an initial ownership report. He directly holds 940,787 ordinary shares and options on 9,117 ordinary shares at an exercise price of $7.6200 expiring on November 4, 2035. As of this filing, 759 option shares are vested and exercisable, with the remainder vesting in 11 equal quarterly installments beginning May 4, 2026, subject to his continued service. Certain option grants are held through a trustee to qualify for Israeli tax benefits under Section 102 of the Israeli Tax Ordinance.
NewcelX Ltd. filed an initial insider ownership report for Chief Financial Officer Hagai Omri, disclosing an option to purchase 11,396 ordinary shares. The option has an exercise price of $7.6200 per share and expires on November 4, 2035.
As of the filing date, options to purchase 949 ordinary shares are vested and exercisable. The remaining options vest in 11 equal quarterly installments beginning on May 4, 2026, subject to Omri’s continued service with the company.
NewcelX Ltd. director Samuel Olivier reported his initial beneficial ownership of stock options in the company. He holds options to purchase 9,117 and 13,676 ordinary shares, each with an exercise price of $7.6200 and expirations on November 4, 2035 and November 27, 2035.
According to the footnotes, as of this filing, options over 759 and 1,139 ordinary shares are already vested and exercisable. The remaining options vest in 11 equal quarterly installments beginning on May 4, 2026, subject to Olivier’s continued service with the company.
NewcelX Ltd. director Oren Liora filed an initial ownership report showing options to purchase 9,117 ordinary shares at an exercise price of 7.6200, expiring on November 4, 2035. As of this filing, 759 options are vested and exercisable, with the remainder vesting in 11 equal quarterly installments beginning on May 4, 2026, subject to continued service. Certain options are held through a trustee to qualify for tax benefits under Section 102 of the Israeli Tax Ordinance.
NewcelX Ltd. VP of R&D Molakandov Kfir filed an initial Form 3 showing derivative ownership in company options. He holds an option to purchase 11,396 ordinary shares at an exercise price of 7.620 per share, expiring on November 4, 2035.
As of this filing, options for 949 ordinary shares are vested and currently exercisable. The remaining options vest in 11 equal quarterly installments beginning on May 4, 2026, subject to his continued service. To qualify for Israeli Section 102 tax benefits, these plan securities are registered in the name of a trustee.
NewcelX Ltd. director Iohan Eran Israel filed an initial Form 3 reporting stock option holdings. He holds an option to purchase 9,117 ordinary shares with an exercise price of $7.62 per share, expiring on November 4, 2035.
As of this filing, options for 759 ordinary shares are vested and currently exercisable. The remaining options vest in 11 equal quarterly installments beginning on May 4, 2026, conditioned on his continued service. The options were issued under NewcelX’s 2021 share option plan and are held through a trustee to qualify for Israeli Section 102 tax benefits.
NewcelX Ltd. director Alexander Zwyer filed an initial Form 3 reporting derivative holdings in the company. He holds an option to purchase 50,143 ordinary shares at an exercise price of 7.6200, expiring on November 4, 2035.
A footnote explains that options to purchase 4,178 ordinary shares are currently vested and exercisable. The remaining options vest in 11 equal quarterly installments beginning on May 4, 2026, subject to his continued service.